MatthewDGalskyMD

Genitourinary Oncology, Hematologic Oncology

Professor Director, Genitourinary Medical Oncology Director, Novel Therapeutics Program Mount Sinai School of Medicine

Overview of Dr. Galsky

Dr. Matthew Galsky is an oncologist in New York, NY and is affiliated with The Mount Sinai Hospital. He received his medical degree from Tufts University School of Medicine and has been in practice 19 years. Dr. Galsky accepts several types of health insurance, listed below. He is one of 190 doctors at The Mount Sinai Hospital who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
10 E 102nd St
New York, NY 10029
Book by Phone+1(415) 944-3143

Fax+1 212-423-0522

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2001 - 2004
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1998 - 2001
Tufts University School of MedicineClass of 1998

Certifications & Licensure

NY State Medical License 2001 - 2025
NV State Medical License 2006 - 2011
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies Start of enrollment: 2009 Dec 11
Completed
Phase 1
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Start of enrollment: 2010 Jan 01
Completed
Phase 1, Phase 2
Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma Start of enrollment: 2010 Jun 01
Withdrawn
Phase 2
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma Start of enrollment: 2010 Dec 01
Terminated
Phase 2
Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma Start of enrollment: 2011 Feb 01
Terminated
Phase 2
Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma Start of enrollment: 2011 Mar 01
Terminated
Phase 1, Phase 2
First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma Start of enrollment: 2012 Jan 01
Completed
Phase 2
A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer Start of enrollment: 2012 Dec 01
Terminated
Phase 2
Abiraterone Acetate Trial in African American Prostate Cancer Patients Start of enrollment: 2012 Dec 01
Terminated
Phase 2
Immune Monitoring on Sipuleucel-T Start of enrollment: 2012 Jun 01
Completed
Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer Start of enrollment: 2015 Nov 11
Completed
Phase 2
Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer Start of enrollment: 2019 May 08
Completed
Phase 1
Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations Start of enrollment: 2018 Apr 17
Completed
Phase 2
Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer Start of enrollment: 2018 May 10
Completed
Phase 2
Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer Start of enrollment: 2018 Nov 12
Active, not recruiting
Phase 2
Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing Start of enrollment: 2018 Jul 13
Completed
Phase 2
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies Start of enrollment: 2019 May 17
Recruiting
Phase 1
Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations Start of enrollment: 2019 Jun 21
Completed
Phase 1
Roles: Principal Investigator, Contact
Pembrolizumab in Muscle-invasive Bladder Cancer Start of enrollment: 2022 Jul 13
Recruiting
Phase 2
Roles: Sponsor-Investigator, Contact, Principal Investigator
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 Start of enrollment: 2023 Sep 22
Recruiting
Phase 3
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

531 citations
Treatment of muscle-invasive and advanced bladder cancer in 2020.
Vaibhav G. Patel, William Oh, Matthew D. Galsky
CA. 2020-09-01
427 citations
Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy
Matthew D. Galsky, Noah M. Hahn, Jonathan E. Rosenberg, Guru Sonpavde, Thomas E. Hutson
Journal of Clinical Oncology. 2011-06-10
48 citations
Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States.
Matthew D. Galsky, Sumanta K. Pal, Shih-Wen Lin, Sarika Ogale, Marko Zivkovic
Bladder Cancer. 2018-04-26

Journal Articles

Identification of microR-106b as a Prognostic Biomarker of p53-like Bladder Cancers by ActMiR
Matthew D Galsky, William K Oh, Nature

Lectures

A phase III, randomized, open label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SOC) chemotherapy and durvalumab in ...
2019 ASCO Annual Meeting - 6/1/2019
Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (m...
2019 ASCO Annual Meeting - 6/1/2019
Is there a difference in PD-1 / PD-L1 inhibitors for urothelial cancer? Continuous Evolution of a Phase I Trial Into An FDA Package
2018 ASCO Annual Meeting - Chicago, Illinois - 05/31/2018

Authored Content

PD-1/PD-L1 Inhibition in Bladder Cancer Now and in the Future, Part 1March 2023

Press Mentions

Immunotherapy After Surgery Is Beneficial for High-Risk Bladder Cancer PatientsApril 3rd, 2023
CheckMate 274: Continued Disease-Free Survival Benefits with Adjuvant Nivolumab in High-Risk Urothelial CarcinomaMarch 8th, 2023
CheckMate 274 Follow up Data Boost Nivolumab Potential for High-Risk Bladder CancerMarch 8th, 2023
Join now to see all

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
GHI PPO
Great West PPO
HIP of New York - Select PPO
Humana ChoiceCare Network PPO
MagnaCare PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment